| scholarly article | Q13442814 |
| P356 | DOI | 10.1164/RCCM.200504-595OC |
| P8608 | Fatcat ID | release_vj3mdaepinggjoqbzo32bk4scq |
| P698 | PubMed publication ID | 16166620 |
| P2093 | author name string | Richard W Costello | |
| Peter M A Calverley | |||
| Paul P Walker | |||
| Nicola J Stevenson | |||
| P2860 | cites work | Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology | Q22299204 |
| Regional chest wall volumes during exercise in chronic obstructive pulmonary disease | Q24678673 | ||
| Development, validity and responsiveness of the Clinical COPD Questionnaire | Q24800304 | ||
| High-dose inhaled albuterol in severe chronic airflow limitation | Q28339412 | ||
| Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease | Q28346514 | ||
| Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper | Q29614960 | ||
| Toward a consensus definition for COPD exacerbations | Q33937749 | ||
| Enhancing physical performance in chronic obstructive pulmonary disease | Q34106173 | ||
| Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation | Q34257204 | ||
| Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial | Q34504803 | ||
| Bronchodilator reversibility testing in chronic obstructive pulmonary disease | Q34535816 | ||
| Impact of preventing exacerbations on deterioration of health status in COPD. | Q34548347 | ||
| Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease | Q35534824 | ||
| Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations | Q35535368 | ||
| Effect of oxygen on recovery from maximal exercise in patients with chronic obstructive pulmonary disease | Q35536935 | ||
| Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial | Q35537967 | ||
| Pathophysiology of airflow limitation in chronic obstructive pulmonary disease | Q35869635 | ||
| Acute hypercapnic respiratory failure in patients with chronic obstructive lung disease: risk factors and use of guidelines for management | Q36255168 | ||
| Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease | Q43616364 | ||
| Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease | Q48631503 | ||
| Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. | Q50680798 | ||
| Forced oscillation total respiratory resistance and spontaneous breathing lung resistance in COPD patients. | Q52204619 | ||
| Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. | Q53577143 | ||
| Intrinsic PEEP and arterial PCO2 in stable patients with chronic obstructive pulmonary disease. | Q54325701 | ||
| Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey | Q57786024 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic obstructive pulmonary disease | Q199804 |
| P304 | page(s) | 1510-1516 | |
| P577 | publication date | 2005-09-15 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease | |
| P478 | volume | 172 |
| Q51546661 | A risk stratification tool for exacerbations of COPD: time to switch to DECAF. |
| Q35046919 | Admission prevention in COPD: non-pharmacological management |
| Q40573171 | An impulse oscillometry system is less efficient than spirometry in tracking lung function improvements after intravenous antibiotic therapy in pediatric patients with cystic fibrosis |
| Q96135220 | An overview of exacerbations of chronic obstructive pulmonary disease: Can tests of small airways' function guide diagnosis and management? |
| Q47661696 | Association between respiratory impedance measured by forced oscillation technique and exacerbations in patients with COPD. |
| Q47704663 | Balance and Falls in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Prospective Study |
| Q37815483 | Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD. |
| Q36432095 | COPD exacerbations . 3: Pathophysiology |
| Q30480789 | COPD exacerbations. 4: Prevention |
| Q36203144 | COPD exacerbations.5: management |
| Q36926629 | COPD exacerbations: defining their cause and prevention |
| Q33591899 | Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update |
| Q39084093 | Changes of Respiratory Mechanics in COPD Patients from Stable State to Acute Exacerbations with Respiratory Failure |
| Q36918970 | Day-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary disease |
| Q85830167 | Dynamic hyperinflation correlates with exertional oxygen desaturation in patients with chronic obstructive pulmonary disease |
| Q33441638 | Dynamic lung hyperinflation and its clinical implication in COPD |
| Q33827166 | Dynamics of inflammation resolution and symptom recovery during AECOPD treatment |
| Q36923028 | Dyspnea and activity limitation in COPD: mechanical factors |
| Q36636050 | Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations |
| Q35623972 | Expiratory flow limitation relates to symptoms during COPD exacerbations requiring hospital admission. |
| Q55223245 | Functional respiratory imaging: heterogeneity of acute exacerbations of COPD. |
| Q51026454 | Gas exchange response to short-acting beta2-agonists in chronic obstructive pulmonary disease severe exacerbations. |
| Q41441617 | Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus |
| Q47991029 | Health status assessment in routine clinical practice: the chronic obstructive pulmonary disease assessment test score in outpatients |
| Q30846957 | Home monitoring of breathing rate in people with chronic obstructive pulmonary disease: observational study of feasibility, acceptability, and change after exacerbation |
| Q37017336 | Hyperinflation and its management in COPD |
| Q45803920 | Impact and prevention of severe exacerbations of COPD: a review of the evidence |
| Q48487432 | Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease |
| Q37762827 | Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial |
| Q35896796 | Inspiratory capacity as a preoperative assessment of patients undergoing thoracic surgery |
| Q38243468 | Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment |
| Q35225129 | Management of patients during and after exacerbations of chronic obstructive pulmonary disease: the role of primary care physicians |
| Q36166290 | Measurement of physiological recovery from exacerbation of chronic obstructive pulmonary disease using within-breath forced oscillometry |
| Q36374863 | Neural respiratory drive predicts clinical deterioration and safe discharge in exacerbations of COPD |
| Q38066983 | New physiological insights into dyspnea and exercise intolerance in chronic obstructive pulmonary disease patients |
| Q38083537 | No room to breathe: the importance of lung hyperinflation in COPD. |
| Q34684239 | Novel insights into the aetiology and pathophysiology of increased airway inflammation during COPD exacerbations |
| Q37029615 | Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease |
| Q37724621 | Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium |
| Q37319950 | Role of macrolide therapy in chronic obstructive pulmonary disease |
| Q60045112 | Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial |
| Q36469780 | Spirometric correlates of dyspnea improvement among emergency department patients with chronic obstructive pulmonary disease exacerbation |
| Q55005612 | Static and dynamic hyperinflation during severe acute exacerbations of chronic obstructive pulmonary disease. |
| Q37200990 | Targeting the COPD exacerbation |
| Q36239310 | Techniques of assessing small airways dysfunction |
| Q36877469 | The airway response to deep inspirations decreases with COPD severity and is associated with airway distensibility assessed by computed tomography |
| Q36760103 | The clinical importance of dynamic lung hyperinflation in COPD. |
| Q39668285 | The effect of transcutaneous electrical nerve stimulation in patients with acute exacerbation of chronic obstructive pulmonary disease: randomised controlled trial |
| Q34910141 | The efficacy and safety of cilomilast in COPD. |
| Q46966092 | The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide |
| Q46528034 | The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease |
| Q36470462 | Update in chronic obstructive pulmonary disease 2005. |
| Q36926626 | What have we learned from large drug treatment trials in COPD? |
| Q80118609 | [Changes in inspiratory capacity during acute respiratory failure in COPD patients] |
| Q83781465 | [Evaluation and follow up of hyperinflation in COPD] |
Search more.